Published • loading... • Updated
Abeona Therapeutics: Q3 Earnings Snapshot – WTOP News
The company said ZEVASKYN revenue rose 18% as six patients were treated and eight qualified treatment centers were activated.
- On Monday, Abeona Therapeutics reported third-quarter revenue of $13.5 million, an 18% increase from the prior quarter, while acquiring ABO-801 from Ellodi Pharmaceuticals to expand its orphan drug pipeline.
- Eosinophilic esophagitis affects 360,000 patients in the U.S. with limited effective oral treatment options; ABO-801, a once-daily orally disintegrating tablet, holds potential for over $750 million in annual peak revenue.
- Abeona posted a net loss of $4.8 million for the third quarter and held $134.9 million in cash as of September 30. Six patients received ZEVASKYN treatment, bringing the total to 15 since launch.
- Eight qualified treatment centers are now activated in the ZEVASKYN network, with management targeting 10 manufacturing slots per month by mid-2027 to expand patient access and reduce treatment scheduling variability.
- Supported by a $30 million private placement, Abeona plans to initiate a Phase III trial for ABO-801 in mid-2027 while strengthening its commercial infrastructure for potential market entry.
Insights by Ground AI
10 Articles
10 Articles
Abeona Therapeutics (NASDAQ:ABEO) Posts Earnings Results, Beats Estimates By $0.06 EPS
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) issued its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.06. The business had revenue of $13.49 million for the quarter, compared to analyst estimates of $14.82 million.
·Sioux Falls, United States
Read Full Article
Abeona Therapeutics: Q3 Earnings Snapshot – WTOP News
CLEVELAND (AP) — CLEVELAND (AP) — Abeona Therapeutics Inc. (ABEO) on Monday reported a loss of $4.8 million in its third quarter. The Cleveland-based company said it had a loss of 8 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a...
·Chevy Chase, United States
Read Full Article
Coverage Details
Total News Sources10
Leaning Left1Leaning Right1Center6Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
13%
C 75%
12%
Factuality
To view factuality data please Upgrade to Premium
